Fig. 2: Efficacy of HLA-I Antigen Presentation Score (HAPS) in predicting immune checkpoint inhibitor (ICI) outcomes.

A, B Significant association between high HAPS and improved overall survival (OS) after receiving ICIs in the Validation 1 and 2 sets (Kaplan–Meier analysis with the log-rank test). Source data are provided as a Source Data file. C Significantly prolonged OS in the high HAPS subgroup (by multivariate Cox analysis) (n = 717). The error bars indicate 95%CI for HR. Source data are provided as a Source Data file. D Significant association between high HAPS and improved progression-free survival after receiving ICIs in five ICI-treated cohorts (Kaplan–Meier analysis with the log-rank test). Source data are provided as a Source Data file. E No significant difference in OS between high and low HAPS subgroups in The Cancer Genome Atlas database (Kaplan–Meier analysis with the log-rank test). Source data are provided as a Source Data file. F Significant difference in HAPS between durable clinical benefit and non-durable benefit subgroups using the Wilcoxon test and Fisher’s exact test (two tailed) (N = 562). In the box plots, center line corresponds to median, box boundaries correspond to the first and third quartiles, the upper whisker is max and lower whisker is min. Source data are provided as a Source Data file. G Distribution of HAPS in complete response, partial response, stable disease, and progressive disease subgroups. Source data are provided as a Source Data file. H, I Association between high HAPS and improved OS after receiving ICIs in the Wang Cohort (Wang-Tissue, n = 35; Wang-Blood, n = 58; samples were sequenced using a 1021-gene panel) (Kaplan–Meier analysis with the log-rank test). Source data are provided as a Source Data file. J Distribution of tissue and blood panel-based HAPS.